SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on April 30, 2002; DOI 10.1182/blood-2002-01-0335. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-01-0335v1 100/4/1168    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Zangari, M. Articles by Tricot, G. Search for Related Content PubMed PubMed Citation Articles by Zangari, M. Articles by Tricot, G. Related Collections Hemostasis, Thrombosis, and Vascular Biology Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 August 2002, Vol. 100, No. 4, pp. 1168-1171 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy Maurizio Zangari, Eric Siegel, Bart Barlogie, Elias Anaissie, Fariba Saghafifar, Athanasios Fassas, Christopher Morris, Louis Fink, and Guido Tricot From the Central Arkansas Veterans Healthcare System; and University of Arkansas for Medical Sciences, Little Rock, AR. Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT). Thalidomide has proven activity in refractory multiple myeloma (MM), and although single-agent thalidomide has minimal prothrombogenic activity, its combination with cytotoxic chemotherapy is associated with a significantly increased risk of DVT. We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one. DT-PACE (dexamethasone/thalidomide/cisplatin/doxorubicin/cyclophos- phanide/etoposide) was offered to patients with preceding standard dose therapy, but no prior autotransplantation, while DCEP-T (dexamethasone/cyclophosphamide/etoposide/cisplatin/thalidomide) was administered for relapse after transplantation. If there were signs or symptoms suggestive of DVT, patients received additional investigations, including Doppler ultrasonography, followed by venography if indicated. Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT. A statistical association between the incidence of DVT and combination chemotherapy including doxorubicin (P = .02) was observed; this association was confirmed on multivariate analysis. MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Palumbo, F. Gay, S. Bringhen, A. Falcone, N. Pescosta, V. Callea, T. Caravita, F. Morabito, V. Magarotto, M. Ruggeri, et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma Ann. Onc., June 1, 2008; 19(6): 1160 - 1165. [Abstract] [Full Text] [PDF] A. Palumbo, T. Facon, P. Sonneveld, J. Blade, M. Offidani, F. Gay, P. Moreau, A. Waage, A. Spencer, H. Ludwig, et al. Thalidomide for treatment of multiple myeloma: 10 years later Blood, April 15, 2008; 111(8): 3968 - 3977. [Abstract] [Full Text] [PDF] E. N. Brown and J. D. Herrington Review of the Relationship Between Venous Thromboembolism, Malignancy and Its Treatment Journal of Pharmacy Practice, April 1, 2008; 21(2): 126 - 137. [Abstract] [PDF] R. Manochakian, K. C. Miller, and A. A. Chanan-Khan Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma Oncologist, August 1, 2007; 12(8): 978 - 990. [Abstract] [Full Text] [PDF] P. G. Richardson, C. Mitsiades, R. Schlossman, N. Munshi, and K. Anderson New Drugs for Myeloma Oncologist, June 1, 2007; 12(6): 664 - 689. [Abstract] [Full Text] [PDF] J. Woodley-Cook, L. Y.Y. Shin, L. Swystun, S. Caruso, S. Beaudin, and P. C. Liaw Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway Mol. Cancer Ther., December 1, 2006; 5(12): 3303 - 3311. [Abstract] [Full Text] [PDF] J.-L. Harousseau, S. Jagannath, P. G. Richardson, P. Sonneveld, M. W. Schuster, D.-L. Esseltine, and K. C. Anderson Bortezomib in Combination with High-Dose Dexamethasone (HD dex) and Erythropoietin (EPO) Does Not Result in an Increased Risk of Thromboembolic Complications. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 3543 - 3543. [Abstract] [PDF] M. Adess, R. Eisner, S. Nand, J. Godwin, H. L. Messmore Jr, and W. H. Wehrmacher Thromboembolism in Cancer Patients: Pathogenesis and Treatment Clinical and Applied Thrombosis/Hemostasis, July 1, 2006; 12(3): 254 - 266. [Abstract] [PDF] B. Barlogie, G. Tricot, E. Anaissie, J. Shaughnessy, E. Rasmussen, F. van Rhee, A. Fassas, M. Zangari, K. Hollmig, M. Pineda-Roman, et al. Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma N. Engl. J. Med., March 9, 2006; 354(10): 1021 - 1030. [Abstract] [Full Text] [PDF] S. V. Rajkumar, E. Blood, D. Vesole, R. Fonseca, and P. R. Greipp Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group J. Clin. Oncol., January 20, 2006; 24(3): 431 - 436. [Abstract] [Full Text] [PDF] J. A. Zonder Thrombotic Complications of Myeloma Therapy Hematology, January 1, 2006; 2006(1): 348 - 355. [Abstract] [Full Text] [PDF] M. Cavo, E. Zamagni, P. Tosi, P. Tacchetti, C. Cellini, D. Cangini, A. de Vivo, N. Testoni, C. Nicci, C. Terragna, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma Blood, July 1, 2005; 106(1): 35 - 39. [Abstract] [Full Text] [PDF] G. Palladini, V. Perfetti, S. Perlini, L. Obici, F. Lavatelli, R. Caccialanza, R. Invernizzi, B. Comotti, and G. Merlini The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL) Blood, April 1, 2005; 105(7): 2949 - 2951. [Abstract] [Full Text] [PDF] A. K. Stewart, C. I. Chen, K. Howson-Jan, D. White, J. Roy, M. J. Kovacs, C. Shustik, A. Sadura, L. Shepherd, K. Ding, et al. Results of a Multicenter Randomized Phase II Trial of Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma after Autologous Stem Cell Transplant Clin. Cancer Res., December 15, 2004; 10(24): 8170 - 8176. [Abstract] [Full Text] [PDF] H. Hassoun, L. Reich, V. M. Klimek, T. Kewalramani, M. Dhodapkar, L. Drake, R. Zimman, C. V. Hedvat, T.-F. Julie, F. Martin, et al. Doxorubicin and Dexamethasone Followed by Thalidomide and Dexamethasone (AD-TD) as Initial Therapy for Symptomatic Patients with Multiple Myeloma. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 2409 - 2409. [Abstract] R. A. Kyle and S. V. Rajkumar Multiple Myeloma N. Engl. J. Med., October 28, 2004; 351(18): 1860 - 1873. [Full Text] [PDF] S. Sallah, A. Husain, J. Wan, P. Vos, and N. P. Nguyen The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance Ann. Onc., October 1, 2004; 15(10): 1490 - 1494. [Abstract] [Full Text] [PDF] W. L. Dahut, J. L. Gulley, P. M. Arlen, Y. Liu, K. M. Fedenko, S. M. Steinberg, J. J. Wright, H. Parnes, C. C. Chen, E. Jones, et al. Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer J. Clin. Oncol., July 1, 2004; 22(13): 2532 - 2539. [Abstract] [Full Text] [PDF] S. Kumar, T. E. Witzig, and S. V. Rajkumar Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies J. Clin. Oncol., June 15, 2004; 22(12): 2477 - 2488. [Abstract] [Full Text] [PDF] M. Miceli, R. Atoui, R. Walker, T. Mahfouz, N. Mirza, J. Diaz, G. Tricot, B. Barlogie, and E. Anaissie Diagnosis of Deep Septic Thrombophlebitis in Cancer Patients by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Scanning: A Preliminary Report J. Clin. Oncol., May 15, 2004; 22(10): 1949 - 1956. [Abstract] [Full Text] [PDF] B. Barlogie, J. Shaughnessy, G. Tricot, J. Jacobson, M. Zangari, E. Anaissie, R. Walker, and J. Crowley Treatment of multiple myeloma Blood, January 1, 2004; 103(1): 20 - 32. [Abstract] [Full Text] [PDF] M. A. Dimopoulos, A. Anagnostopoulos, and D. Weber Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives J. Clin. Oncol., December 1, 2003; 21(23): 4444 - 4454. [Abstract] [Full Text] [PDF] S. M. Plum, A. D. Hanson, K. M. Volker, H. A. Vu, B. K. L. Sim, W. E. Fogler, and A. H. Fortier Synergistic Activity of Recombinant Human Endostatin in Combination with Adriamycin: Analysis of in Vitro Activity on Endothelial Cells and in Vivo Tumor Progression in an Orthotopic Murine Mammary Carcinoma Model Clin. Cancer Res., October 1, 2003; 9(12): 4619 - 4626. [Abstract] [Full Text] [PDF] C.-K. Lee, B. Barlogie, N. Munshi, M. Zangari, A. Fassas, J. Jacobson, F. van Rhee, M. Cottler-Fox, F. Muwalla, and G. Tricot DTPACE: An Effective, Novel Combination Chemotherapy With Thalidomide for Previously Treated Patients With Myeloma J. Clin. Oncol., July 15, 2003; 21(14): 2732 - 2739. [Abstract] [Full Text] [PDF] M. S H Lam and R. J Ignoffo A guide to clinically relevant drug interactions in oncology Journal of Oncology Pharmacy Practice, June 1, 2003; 9(2-3): 45 - 85. [Abstract] [PDF] M. Cavo, E. Zamagni, C. Cellini, P. Tosi, D. Cangini, M. Cini, L. Valdre, G. Palareti, L. Masini, S. Tura, et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy Blood, August 28, 2002; 100(6): 2272 - 2272. [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020